Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis

Aim. Increasing evidence supports the role of the gut microbiota in the etiology of ulcerative colitis (UC). Fecal microbiota transplantation (FMT) is a highly effective treatment against recurrent Clostridium difficile infection; however, its efficacy in UC is still controversial. A systematic revi...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaolei Liu, Yan Li, Kaichun Wu, Yongquan Shi, Min Chen
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2021/6612970
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832550973607772160
author Xiaolei Liu
Yan Li
Kaichun Wu
Yongquan Shi
Min Chen
author_facet Xiaolei Liu
Yan Li
Kaichun Wu
Yongquan Shi
Min Chen
author_sort Xiaolei Liu
collection DOAJ
description Aim. Increasing evidence supports the role of the gut microbiota in the etiology of ulcerative colitis (UC). Fecal microbiota transplantation (FMT) is a highly effective treatment against recurrent Clostridium difficile infection; however, its efficacy in UC is still controversial. A systematic review and meta-analysis was conducted to evaluate the efficacy and safety of FMT for treatment of active UC. Methods. We searched Cochrane, Medline, Web of Science, and Embase from inception to February 2020. Randomized controlled trials (RCTs) recruiting adults with active UC, which compared FMT with controls, were eligible. The primary outcome was combined clinical remission with endoscopic remission/response. Secondary outcomes included clinical remission, endoscopic remission, and serious adverse events. Relative risk (RR) with 95% confidence interval (CI) is reported. Results. Five RCTs with 292 participants were eligible for inclusion. When data were pooled for all patients, FMT was associated with a higher combined clinical remission with endoscopic remission/response; the RR of combined outcome not achieving after FMT vs. control was 0.79 (95% CI 0.70-0.88). FMT delivered via lower gastrointestinal route was superior to upper gastrointestinal route with regard to combined clinical remission with endoscopic remission/response (RR=0.79, 95% CI 0.70-0.89). FMT with pooled donor stool (RR=0.69, 95% CI 0.56-0.85) and higher frequency of administration (RR=0.76, 95% CI 0.62-0.93) may be more effective with regard to clinical remission. There was no statistically significant difference in serious adverse events with FMT compared with controls (RR=0.98, 95% CI 0.93-1.03). Conclusion. FMT shows a promising perspective with comparable safety and favorable clinical efficacy for the treatment of active UC in the short term. However, further larger, more rigorously conducted RCTs of FMT in UC are still needed in order to resolve the controversial questions.
format Article
id doaj-art-55ec662193f848c7b69c97ea8e8489c8
institution Kabale University
issn 1687-6121
1687-630X
language English
publishDate 2021-01-01
publisher Wiley
record_format Article
series Gastroenterology Research and Practice
spelling doaj-art-55ec662193f848c7b69c97ea8e8489c82025-02-03T06:05:16ZengWileyGastroenterology Research and Practice1687-61211687-630X2021-01-01202110.1155/2021/66129706612970Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-AnalysisXiaolei Liu0Yan Li1Kaichun Wu2Yongquan Shi3Min Chen4Department of Medical Insurance, Xijing Hospital, Air Force Medical University, Xi’an, Shaanxi Province 710032, ChinaDepartment of Medical Insurance, Xijing Hospital, Air Force Medical University, Xi’an, Shaanxi Province 710032, ChinaState Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi’an, Shaanxi Province 710032, ChinaState Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi’an, Shaanxi Province 710032, ChinaState Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi’an, Shaanxi Province 710032, ChinaAim. Increasing evidence supports the role of the gut microbiota in the etiology of ulcerative colitis (UC). Fecal microbiota transplantation (FMT) is a highly effective treatment against recurrent Clostridium difficile infection; however, its efficacy in UC is still controversial. A systematic review and meta-analysis was conducted to evaluate the efficacy and safety of FMT for treatment of active UC. Methods. We searched Cochrane, Medline, Web of Science, and Embase from inception to February 2020. Randomized controlled trials (RCTs) recruiting adults with active UC, which compared FMT with controls, were eligible. The primary outcome was combined clinical remission with endoscopic remission/response. Secondary outcomes included clinical remission, endoscopic remission, and serious adverse events. Relative risk (RR) with 95% confidence interval (CI) is reported. Results. Five RCTs with 292 participants were eligible for inclusion. When data were pooled for all patients, FMT was associated with a higher combined clinical remission with endoscopic remission/response; the RR of combined outcome not achieving after FMT vs. control was 0.79 (95% CI 0.70-0.88). FMT delivered via lower gastrointestinal route was superior to upper gastrointestinal route with regard to combined clinical remission with endoscopic remission/response (RR=0.79, 95% CI 0.70-0.89). FMT with pooled donor stool (RR=0.69, 95% CI 0.56-0.85) and higher frequency of administration (RR=0.76, 95% CI 0.62-0.93) may be more effective with regard to clinical remission. There was no statistically significant difference in serious adverse events with FMT compared with controls (RR=0.98, 95% CI 0.93-1.03). Conclusion. FMT shows a promising perspective with comparable safety and favorable clinical efficacy for the treatment of active UC in the short term. However, further larger, more rigorously conducted RCTs of FMT in UC are still needed in order to resolve the controversial questions.http://dx.doi.org/10.1155/2021/6612970
spellingShingle Xiaolei Liu
Yan Li
Kaichun Wu
Yongquan Shi
Min Chen
Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
Gastroenterology Research and Practice
title Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
title_full Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
title_fullStr Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
title_full_unstemmed Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
title_short Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
title_sort fecal microbiota transplantation as therapy for treatment of active ulcerative colitis a systematic review and meta analysis
url http://dx.doi.org/10.1155/2021/6612970
work_keys_str_mv AT xiaoleiliu fecalmicrobiotatransplantationastherapyfortreatmentofactiveulcerativecolitisasystematicreviewandmetaanalysis
AT yanli fecalmicrobiotatransplantationastherapyfortreatmentofactiveulcerativecolitisasystematicreviewandmetaanalysis
AT kaichunwu fecalmicrobiotatransplantationastherapyfortreatmentofactiveulcerativecolitisasystematicreviewandmetaanalysis
AT yongquanshi fecalmicrobiotatransplantationastherapyfortreatmentofactiveulcerativecolitisasystematicreviewandmetaanalysis
AT minchen fecalmicrobiotatransplantationastherapyfortreatmentofactiveulcerativecolitisasystematicreviewandmetaanalysis